IGF-1 LR3.
Long-acting IGF-1 analogue — anabolic and neurotrophic signalling.
Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.
- ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
- ✓Patient-named prescription only — dispensed against a valid Rx.
- ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
- ✓Cold-chain shipping across EU/EEA — 2–5 working days.
About IGF-1 LR3.
IGF-1 LR3 is a synthetic 83-amino-acid analogue of insulin-like growth factor 1, with a 13-amino-acid extension at the N-terminus and an arginine-3 substitution that prevents binding by IGFBPs. The result: a half-life of ~20–30 hours vs. ~10 minutes for native IGF-1.
The molecule is potent. It must be prescribed carefully — IGF-1 drives both desired and undesired anabolic effects.
IGF-1 LR3 binds the IGF-1 receptor on most cell types and triggers PI3K-Akt-mTOR signalling, driving protein synthesis, cell proliferation and tissue repair. Its escape from IGFBP binding gives it free access to receptors throughout the body.
Subcutaneous injection, typically 20–40 mcg daily, cycles of 4 weeks with re-evaluation. Local injection close to an injury site is preferred when appropriate.
Your physician sets the prescription. This is descriptive information, not a self-administration guide.
Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.
- INN / Name
- IGF-1 LR3
- Form
- Lyophilised vial · subcutaneous injection
- Strength
- 1mg vial
- Manufacturing
- EU-GMP Annex 1 · Grade A/B
- Endotoxins
- European Pharmacopoeia 2.6.14 · LAL assay
- Identity & purity
- HPLC + MS · > 98%
- Cold chain
- Validated 2–8 °C, monitored end-to-end
- Regulatory basis
- Directive 2001/83/EC · Article 5(1)
2–5 working days
EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.
Magistral preparation
Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.
EU prescription recognition
Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.